8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2014

Shire plc

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

(State or other jurisdiction of incorporation)

0-29630	98-0601486
(Commission File Number)	(IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

(Address of principal executive offices)	(Zip code)
Registrant's telephone number, including area code	+353 1 429 7700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01. Other Events

Shire plc have issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d)  Exhibits.  The following exhibit is filed herewith:

99.1 Press Release dated July 11, 2014

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ T May
	Name:	Tatjana May
	Title:	General Counsel

Dated: July 11, 2014

EXHIBIT INDEX
Number	Description
99.1	Press Release dated July 11, 2014

EX-99.1

Exhibit 99.1

Press Release
www.shire.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE

OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO

DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT

LAWS OF SUCH JURISDICTION.

For immediate release 11 July 2014

Shire plc

Statement re: Media Speculation

Shire plc (“Shire” or the “Company”) (LSE: SHP, NASDAQ: SHPG) notes the Bloomberg article this afternoon.  Shire confirms it has held a meeting with representatives of AbbVie.

This statement is being made by Shire without the prior agreement or approval of AbbVie.

A further update will be made when appropriate.  Shareholders are strongly advised to take no action in relation to AbbVie’s proposal.  There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.

CONTACTS

Shire
Stephanie Fagan	+1 201 572 9581
FTI Consulting (Media Adviser to the Company)
Andrew Lorenz (London)	+44 77 7564 1807
Ben Atwell (London)	+44 20 3727 1000
David B. Roady (New York)	+1 212 850 5600
Robert Stanislaro (New York)	+1 212 850 5600

A copy of this announcement will be available at www.shire.com.  The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

2